Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's relebactam dubbed qualified infectious disease product

This article was originally published in Scrip

Executive Summary

Merck revealed on 4 September its investigational beta-lactamase inhibitor relebactam (MK-7655) was dubbed a qualified infectious disease product (QIDP) by the FDA.

You may also be interested in...



Keeping Track: Recarbrio Approval Highlights Two-Week Roundup

The latest drug development news and highlights for our US FDA Performance Tracker.

Merck And The 'Strange Business' Of Antibiotics

Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel